Samsung Biologics Webinars
-
CLD To Upstream Optimization: Enhancing Biologics Quality, Productivity
4/30/2025
Explore how advanced cell line development and upstream processing strategies optimize both productivity and therapeutic effectiveness, ensuring the development of high-quality biologics.
-
Bioprocess Optimization: Leveraging Functional DOE With Time-Based Insights
3/5/2025
Explore the key differences between traditional DOE and Functional DOE as Seongjin Kim demonstrates how the latter enhances bioprocess optimization through a fed-batch cell culture example.
-
Introducing 2 New Highly Effective ADC Payloads For Cancer Therapeutics
11/6/2024
Unlock the potential of antibody-drug conjugates (ADCs) by exploring our novel payloads, designed for easy access and evaluation, to accelerate your ADC drug development with proven efficacy and safety.
-
Navigating Challenges During Formulation Development
9/11/2024
Gain valuable knowledge on addressing formulation stability, improving product shelf life, and enhancing overall product performance in biopharmaceutical studies.
-
Formulation Considerations For The Development Of High Concentration Biopharmaceuticals
9/11/2024
This session addresses key obstacles—such as opalescence, viscosity, and aggregation—and present real-world case studies on how composition changes during the concentration process can be effectively characterized.
-
Mitigating Early Development Risks With Samsung Biologics DEVELOPICK™ Platform
6/5/2024
This presentation addresses the critical need for high-throughput, reliable analytical development strategies to support expedited Investigational New Drug (IND) applications.
-
Downstream Strategies To Accelerate Preclinical Development Timelines
4/3/2024
As recombinant protein-based products accelerate toward IND, reliable process development methods are critical to meet demand. Review case studies to learn how expedited timelines can be achieved.
-
Enhancing Quality By Employing Cell Line Replacement, Process Optimization
3/19/2024
Explore how the various proprietary platforms and in-house expertise fit together to enable a range of comprehensive options that can be adapted to fit development strategies.
-
Accelerated Tech Transfer For A COVID-19 Program
This webinar describes the acceleration of tech transfer to enable kickoff to vial thaw for antibody manufacture within three months for a clinical program and five months for process qualification.
-
Continuous Manufacturing: Challenges, Advantages Of N-1 Perfusion
Discover key considerations and challenges in implementing N-1 perfusion technology, as well as the impact of continuous technology on tech transfer and process scale-up.